###begin article-title 0
A Korean Family of Hypokalemic Periodic Paralysis with Mutation in a Voltage-gated Calcium Channel (R1239G)
###end article-title 0
###begin p 1
###xml 533 540 533 540 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CACNA1S</italic>
###xml 687 694 687 694 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CACNA1S</italic>
###xml 346 349 <span type="species:ncbi:9606">boy</span>
###xml 747 750 <span type="species:ncbi:9606">boy</span>
Hypokalemic periodic paralysis (HOPP) is a rare disease characterized by reversible attacks of muscle weakness accompanied by episodic hypokalemia. Recent molecular work has revealed that the majority of familial HOPP is due to mutations in a skeletal muscle voltage-dependent calcium-channel: the dihydropyridine receptor. We report a 13-yr old boy with HOPP from a family in which 6 members are affected in three generations. Genetic examination identified a nucleotide 3705 C to G mutation in exon 30 of the calcium channel gene, CACNA1S. This mutation predicts a codon change from arginine to glycine at the amino acid position #1239 (R1239G). Among the three known mutations of the CACNA1S gene, the R1239G mutation was rarely reported. This boy and the other family members who did not respond to acetazolamide, showed a marked improvement of the paralytic symptoms after spironolactone treatment.
###end p 1
###begin title 2
INTRODUCTION
###end title 2
###begin p 3
###xml 392 393 392 393 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 394 395 394 395 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
Familial hypokalemic periodic paralysis (HOPP) is an autosomal dominant disorder characterized by episodic attacks of muscle weakness with concomitant hypokalemia (<3.5 mEq/L), which usually involves the four limbs. The age at onset of paralytic crises is usually within the first or second decade. The frequency of attacks is maximal between 15 and 35 yr of age and then decreases with age (1-3). The precipitating factors include carbohydrate- or sodium-rich meals, emotional stress, and rest after exercise. The interval between crisis can vary, and may be prolonged with preventive measures, including avoidance of triggering factors, dietary changes, and appropriate medications.
###end p 3
###begin p 4
###xml 104 111 104 111 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CACNA1S</italic>
###xml 139 144 139 144 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SCN4A</italic>
###xml 147 148 147 148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
###xml 149 150 149 150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
###xml 223 230 223 230 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CACNA1S</italic>
###xml 267 268 267 268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 270 271 270 271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 278 285 278 285 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CACNA1S</italic>
###xml 573 574 569 570 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 576 577 572 573 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 578 580 574 576 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 192 200 <span type="species:ncbi:9606">patients</span>
Recent molecular genetic analysis has shown that HOPP is caused by mutations in a calcium channel gene (CACNA1S) or a sodium channel gene (SCN4A) (2-7). However, the majority of familial HOPP patients have mutations in the CACNA1S gene located on chromosome 1q31-32 (8, 9). The CACNA1S gene encodes the alpha1-subunit of a skeletal muscle voltage-gated L-type calcium channel known as the dihydropyridine (DHP) receptor. The phenotypes of each mutation have some differences in the gender penetrance, and the clinical characteristics including the response to medications (4, 9-13).
###end p 4
###begin p 5
###xml 242 244 242 244 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 246 248 246 248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
###xml 298 300 298 300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 14 21 <span type="species:ncbi:9606">patient</span>
###xml 148 156 <span type="species:ncbi:9606">patients</span>
###xml 202 210 <span type="species:ncbi:9606">children</span>
We describe a patient with a mutation of arginine 1239-to-glycine (R1239G) in calcium channel which is the rarest one in the reported familial HOPP patients. In Korea, several cases of familial HOPP in children and adults have been reported (14, 15), but DNA diagnosis for familial HOPP is sparse (16).
###end p 5
###begin title 6
CASE REPORT
###end title 6
###begin p 7
###xml 721 727 721 727 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Fig. 1</xref>
###xml 12 15 <span type="species:ncbi:9606">boy</span>
###xml 594 601 <span type="species:ncbi:9606">patient</span>
A 13-yr old boy presented with near-daily attacks of mild to severe paralysis for the past 8 yr. The symptoms mainly appeared in the morning and he usually awakened with weakness of the four limbs to the point of difficulty in sitting and walking. After the paralytic episode in the morning, he was free of symptoms in the afternoon, but eating high-sodium or carbohydrate foods and rest after vigorous exercise made him weak or completely paralyzed again at any time. In family history, his mother (41 yr old), maternal-grandmother (81 yr old), maternal aunt (55 yr old) and her two sons (the patient's cousins, 23 and 27 yr old) were also suffering from similar attacks of weakness or paralysis throughout their lives (Fig. 1). The severity and frequency of attacks of grandmother and mother has decreased with age. Two cousins of the proband were diagnosed HOPP 8 yr ago at our hospital. They were treated with acetazolamide and potassium supplements. Because there is no effect of such treatment, they stopped taking the drugs and they were lost further medical support.
###end p 7
###begin p 8
###xml 441 448 441 448 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CACNA1S</italic>
###xml 455 462 455 462 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">Table 1</xref>
###xml 595 601 595 601 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Fig. 2</xref>
###xml 172 179 <span type="species:ncbi:9606">patient</span>
###xml 608 615 <span type="species:ncbi:9606">patient</span>
On admission, the proband showed non-specific findings in physical examination, radiologic and laboratory findings including muscle enzymes. During paralytic episodes, the patient showed low serum potassium levels (3.2 mEq/L vs. 4.4 mEq/L between attack) and hypokalemic ECG findings, such as ST segment depression and U-wave. There was no myotonia in EMG findings. DNA examination identified a nucleotide 3705 C to G mutation in exon 30 of CACNA1S gene (Table 1). This mutation predicts codon change from arginine to glycine at amino acid position #1239 of axon 30 in the calcium channel gene (Fig. 2). The patient was treated with spironolactone (25 mg b.i.d.), and he showed a dramatic improvement in his symptoms within 2 days. Other affected members of the family, including two cousins of the proband, have also started taking spironolactone. They could also themselves awaken refresh and move at their will throughout the day.
###end p 8
###begin title 9
DISCUSSION
###end title 9
###begin p 10
###xml 606 608 606 608 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 609 611 609 611 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 41 46 <span type="species:ncbi:9606">human</span>
Periodic paralyses constitute a group of human hereditary muscles disorders. Based on the variations of serum potassium levels during attacks, they can classify as HOPP or hyperkalemic periodic paralysis. Both are inherited via autosomal dominant mode with a high penetrance. HOPP is the most frequent cause of periodic paralysis. The prevalence of HOPP has been estimated at 1/100,000. Although most individuals diagnosed with HOPP in Western countries were familial types, sporadic types with or without underlying diseases, such as thyrotoxicosis and renal tubular acidosis have been reported in Korea (14-16).
###end p 10
###begin p 11
###xml 19 27 19 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CACNL1A3</italic>
###xml 61 62 61 62 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
###xml 63 64 63 64 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 67 74 67 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CACNA1S</italic>
###xml 406 408 379 381 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 410 412 383 385 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
###xml 642 648 603 609 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Fig. 2</xref>
###xml 979 980 940 941 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
###xml 982 983 943 944 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 1088 1089 1049 1050 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 1091 1093 1052 1054 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 1159 1160 1120 1121 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 1391 1397 1352 1358 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Fig. 2</xref>
###xml 1399 1406 1360 1367 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">Table 1</xref>
Three mutations of CACNL1A3 gene are known in familial HOPP (7-9). CACNA1S encodes the alpha1-subunit of a skeletal muscle voltage-gated calcium channel termed the dihydropyridine (DHP) receptor. This channel is composed of five subunits called alpha1, alpha2, beta, gamma, and delta. The alpha1-subunit constitutes the ion-conducting pore, and contains the receptor for dihydropyridine and other ligands (17, 18), whereas the other subunits regulate the function of the alpha1-subunit of the channel. The alpha1-subunit is composed of four transmembrane domains (I to IV), each of them containing six transmembrane alpha helices (S1 to S6) (Fig. 2). The amino-acid substitutions in the three mutations are as follows: the replacement of a positively-charged arginine in position 528 in segment S4 of domain II by a weakly-positive histidine (R528H) and an arginine in position 1239 in the S4 segment of the fourth domain by either an histidine or a glycine (R1239H and R1239G) (7, 9). Molecular studies in Caucasian families demonstrated that R528H and R1239H are predominant mutations (4, 10), whereas the R1239G mutation was only found in a single family (9). The molecular diagnosis for familial HOPP was possible using PCR amplication of genomic DNA followed by restriction-enzyme digestion. By this method, the proband identified that the rare R1239G mutation inherited in his family (Fig. 2, Table 1).
###end p 11
###begin p 12
###xml 48 53 48 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SCN4A</italic>
###xml 321 322 321 322 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 324 325 324 325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
Recently, mutations in the sodium channel gene (SCN4A) in HOPP were reported. The structure of the sodium channel is similar to that of the calcium channel and is composed of 4 domains each with 6 segments. These mutations were found in the domain II of the S4 segment like R528H in the mutations of the calcium channel (4, 6).
###end p 12
###begin p 13
###xml 89 90 89 90 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 92 94 92 94 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 95 97 95 97 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12">12</xref>
###xml 114 116 114 116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 611 612 611 612 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 614 616 614 616 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 730 732 730 732 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 733 735 733 735 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
###xml 779 784 779 784 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SCNA4</italic>
###xml 795 796 795 796 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 827 832 827 832 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SCNA4</italic>
###xml 843 845 843 845 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 1397 1399 1397 1399 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 1400 1402 1400 1402 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B26">26</xref>
###xml 1622 1624 1622 1624 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 320 328 <span type="species:ncbi:9606">patients</span>
###xml 353 361 <span type="species:ncbi:9606">patients</span>
###xml 720 728 <span type="species:ncbi:9606">patients</span>
###xml 755 763 <span type="species:ncbi:9606">patients</span>
###xml 804 811 <span type="species:ncbi:9606">patient</span>
###xml 1188 1196 <span type="species:ncbi:9606">patients</span>
There are several studies for clinical comparisons in families with different mutations (4, 10-12). Elbaz et al. (10) reported that the R528H and the R1239H mutations had the similar mean age of onset, the number of acute attacks, and the precipitating factors. However incomplete penetrance was observed only in female patients with R528 mutation. Our patients appeared to present severe symptoms in males, and an earlier beginning and higher frequency of paralysis symptoms than the previously reported cases. The response to medications also seems to depend upon the mutations underlying periodic paralysis (4, 13). The acetazolamide, a carbonic anhydrase inhibitor, has been considered highly effective in most HOPP patients (19-21). However, several patients with the R672G SCNA4 mutation (4) and a patient with the R672S SCNA4 mutation (13) showed an exacerbation of the symptoms after acetazolamide treatment. Although we did not perform DNA analysis for two cousins of the proband, they experienced an exacerbation of symptoms with acetazolamide treatment 8 yr ago. However, it has not been determined yet that the R1239G mutation is associated with acetazolamide-resistance. Our patients showed a remarkable improvement of symptoms with spironolactone treatment. Spironolactone and its derivatives are alternatives to acetazolamide if it is not effective after the empirical initial use (22-26). The action of the aldosterone antagonists on HOPP is not known. The beneficial effects on HOPP cannot be explained by antagonism to the action of aldosterone on the renal or enteric excretion of sodium and potassium (22). Although recent studies have demonstrated that mutations in the calcium- and sodium channels cause HOPP, the mechanism of these channels in the pathophysiology of HOPP has not clearly been defined.
###end p 13
###begin p 14
###xml 239 241 239 241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
###xml 243 245 243 245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B28">28</xref>
Several complications during the clinical courses have been reported. Vascular myopathy, unexpected acute paralysis or cardiac arrhythmia with hypokalemia, and possibly malignant hyperthermia associated with anesthesia have been reported (27, 28).
###end p 14
###begin p 15
In conclusion, genetic diagnosis of familial HOPP is very useful for making a confirmative diagnosis, providing genetic counseling for the family members and as well as for providing the appropriate treatment.
###end p 15
###begin title 16
ACKNOWLEDGEMENT
###end title 16
###begin p 17
We are grateful to Dr Katherine B Sims, Massachusetts General Hospital, Harvard University, for performing DNA analysis.
###end p 17
###begin article-title 18
Periodic paralysis
###end article-title 18
###begin article-title 19
Channelopathies
###end article-title 19
###begin article-title 20
Hypokalemic periodic paralysis: an autosomal dominant muscle disorder caused by mutations in a voltage-gated calcium channel
###end article-title 20
###begin article-title 21
Hypokalemic periodic paralysis type 2 caused by mutations at codon 672 in the muscle sodium channel gene SCN4A
###end article-title 21
###begin article-title 22
Severe prognosis in a large family with hypokalemic periodic paralysis
###end article-title 22
###begin article-title 23
A novel sodium channel mutation in a family with hypokalemic periodic paralysis
###end article-title 23
###begin article-title 24
A calcium channel mutation causing hypokalemic periodic paralysis
###end article-title 24
###begin article-title 25
Mapping of the hypokalemic periodic paralysis to chromosome 1q31-q32 in three European families
###end article-title 25
###begin article-title 26
Dihydropyridine receptor mutations cause hypokalemic periodic paralysis
###end article-title 26
###begin article-title 27
Hypokalemic periodic paralysis and the dihydropyridine receptor (CACNL1A 3): genotype/phenotype correlations for two predominant mutations and evidence for the absence of a founder effect in 16 caucasian families
###end article-title 27
###begin article-title 28
Hypokalemic periodic paralysis mutations: confirmation of mutation and analysis of founder effect
###end article-title 28
###begin article-title 29
Genotype-phenotype correlations of DHP receptor alpha 1-subunit gene mutations causing hypokalemic periodic paralysis
###end article-title 29
###begin article-title 30
Sodium channel inactivation defects are associated with acetazolamide-exacerbated hypokalemic periodic paralysis
###end article-title 30
###begin article-title 31
A case of familial hypokalemic periodic paralysis
###end article-title 31
###begin article-title 32
Two cases of familial hypokalemic periodic paralysis
###end article-title 32
###begin article-title 33
###xml 66 74 <span type="species:ncbi:9606">patients</span>
Identification of mutations including de novo mutations in Korean patients with hypokalemic periodic paralysis
###end article-title 33
###begin article-title 34
Structure and function of voltage-sensitive ion channels
###end article-title 34
###begin article-title 35
Induction of calcium currents by the expression of the alpha1-subunit of the dihydropyridine receptor from skeletal muscle
###end article-title 35
###begin article-title 36
Acetazolamide treatment of hypokalemic periodic paralysis
###end article-title 36
###begin article-title 37
Acetazolamide opens the muscular KCa2+ channel: a novel mechanism of action that may explain the therapeutic effect of the drug in hypokalemic periodic paralysis
###end article-title 37
###begin article-title 38
Familial hypokalemic periodic paralysis. Clinical, diagnostic and therapeutic aspects
###end article-title 38
###begin article-title 39
Periodic paralysis with response to spironolactone
###end article-title 39
###begin article-title 40
Hypokalemic periodic paralysis exacerbated by acetazolamide
###end article-title 40
###begin article-title 41
Hypokalemic periodic paralysis unresponsive to acetazolamide
###end article-title 41
###begin article-title 42
Hypokalemic periodic paralysis with unusual responses to acetazolamide and sympathomimetics
###end article-title 42
###begin article-title 43
Randomized trials of dichlorphenamide in the periodic paralysis. Working Group on Periodic Paralysis
###end article-title 43
###begin article-title 44
###xml 28 35 <span type="species:ncbi:9606">patient</span>
Malignant hyperthermia in a patient with hypokalemic periodic paralysis
###end article-title 44
###begin article-title 45
Anesthetic experiences in a family with hypokalemic familial periodic paralysis
###end article-title 45
###begin p 46
Pedigree of the HOPP family. The dark symbols are affected individuals. The proband is indicated by an arrow. The age of the family members is designated by the number.
###end p 46
###begin p 47
Schematic diagram of the DHP receptor alpha1-subunit composed of four domains of an internal homology (DI to DIV) connected by intracellular loops. The R1239G mutation substitutes a positively-charged arginine located within segment DIVS4 by a neutral glycine.
###end p 47
###begin p 48
Results of DNA analysis in the proband
###end p 48
###begin p 49
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">*</sup>
*Controls used in this test are the corresponding mutants.
###end p 49

